Join to access to all OVN content. Join for Free

Results for 'patient education in research'

Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals
OVN Avatar R. Kurzrock, L.A. Gurski, R.W. Carlson, D.S. Ettinger, S.M. Horwitz, S.K. Kumar, L. Million, M. von Mehren, A.B. Benson III
Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals

oncology, guidelines, off-label drug use

The analysis reviewed 113 NCCN recommendations, focusing on 44 off-label uses of drugs. 14 of these off-label recommendations were later FDA-approved or backed by RCT data. 13 recommendations were minor extrapolations from the FDA label or actually on-label. Of the remaining 17 extrapolations…

Aug 2nd • 8 mins read

Transforming oncology: Five frontiers driving progress in cancer care
Partner Avatar iNIZIO
Transforming oncology: Five frontiers driving progress in cancer care

Thought Leadership, Oncology

From biomarker-driven breakthroughs to AI-powered early detection and a renewed commitment to equity and patient centricity, the past 12 months have seen major strides across cancer research, treatment, and communication. At Inizio, we’ve had a front-row seat to this transformation, supporting…

May 16th • 5 mins read

The Case for Real-world Evidence in the Future of Clinical Research on Chronic Myeloid Leukemia
OVN Avatar Jonathon Webster, MD and B. Douglas Smith, MD
The Case for Real-world Evidence in the Future of Clinical Research on Chronic Myeloid Leukemia

Real world data, FDA, RCT, RWE, RWD

In light of recently published guidelines from the US Food and Drug Administration (FDA) on the communication of real-world data (RWD) and real-world evidence (RWE) to support regulatory decision making, it is important to understand the following key points and concepts: Development of RWD and R…

Jan 29th • 10 mins read

Related Topics

Loading...